Deletion of any part of the BCR or ABL gene on the derivative chromosome 9 is a poor prognostic marker in chronic myelogenous leukemia

Cancer Genetics and Cytogenetics

Volumn 166, Issue 1, 2006, Pages 65-73

  Lee, Young Kyung ^a   Kim, Young Ree ^b   Min, Hyun Chung ^c,d   Oh, Bo Ra ^c,d   Kim, Tae Young ^c,d   Kim, Young Soo ^e   Cho, Han Ik ^e   Kim, Hee Chan ^f   Lee, Yun Song ^g   Lee, Dong Soon ^c,d,e  

^a Hallym University College of Medicine   (South Korea)

^b Jeju National University School of Medicine   (South Korea)

^c Cancer Res Ctr Cancer Res I   (South Korea)

^d National Research Laboratory of Molecular Imaging   (South Korea)

^e Department of Molecular Genomics ^*  (South Korea)

^f Seoul National University College of Medicine   (South Korea)

^g Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN;

ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW; CANCER SURVIVAL; CHROMOSOME 9; CHRONIC MYELOID LEUKEMIA; DISEASE ASSOCIATION; EVALUATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE IDENTIFICATION; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MOLECULAR PROBE; PRIORITY JOURNAL; PROGNOSIS; SCHOOL CHILD;

EID: 33646014792     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2005.08.028     Document Type: Article

References (24)

1. Melo J.V., Gordon D.E., Cross N.C.P., and Goldman J.M. The ABL-BCR fusion gene is expressed in chronic myeloid leukemia. Blood 81 (1993) 158-165
2. Melo J.V., Hochhaus A., Yan X.H., and Goldman J.M. Lack of correlation between ABL-BCR expression and response to interferon-alpha in chronic myeloid leukaemia. Br J Haematol 92 (1996) 684-686
3. Loncarevic I.F., Römer J., Starke H., Heller A., Bleck C., Ziegler M., Fiedler W., Liehr T., Clement J.H., and Claussen U. Heterogenic molecular basis for loss of ABL1-BCR transcription: deletions in der(9)t(9;22) and variants of standard t(9;22) in BCR-ABL1-positive chronic myeloid leukemia. Genes Chromosomes Cancer 34 (2002) 193-200
4. Huntly B.J., Bench A.J., Delabesse E., Reid A.G., Li J., Scott M.A., Campbell L., Byrne J., Pinto E., Brizard A., Niedermeiser D., Nacheva E.P., Guilhot F., Deininger M., and Green A.R. Derivative chromosome 9 deletions in chronic myeloid leukemia: poor prognosis is not associated with loss of ABL-BCR expression, elevated BCR-ABL levels, or karyotypic instability. Blood 99 (2002) 4547-3
5. Sinclair P.B., Nacheva E.P., Leversha M., Telford N., Chang J., Reid A., Bench A., Champion K., Huntly B., and Green A.R. Large deletions at the t(9;22) breakpoint are common and may identify a poor-prognosis subgroup of patients with chronic myeloid leukemia. Blood 95 (2000) 738-744
6. González F.A., Anguita E., Mora A., Asenjo S., López I., Polo M., and Villegas A. Deletion of BCR region 3' in chronic myelogenous leukemia. Cancer Genet Cytogenet 130 (2001) 68-74
7. Faderl S., Talpaz M., Estrov Z., O'Brien S., Kurzrock R., and Kantarjian H.M. The biology of chronic myeloid leukemia. N Engl J Med 341 (1999) 164-172
8. Kantarjian H.M., Dixon D., Keating M.J., Talpaz M., Walters R.S., McCredie K.B., and Freireich E.J. Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 61 (1988) 1441-1446
9. Gribble S.M., Sinclair P.B., Grace C., Green A.R., and Nacheva E.P. Comparative analysis of G banding, chromosome painting, locus-specific fluorescence in situ hybridization, and comparative genomic hybridization in chronic myeloid leukemia blast crisis. Cancer Genet Cytogenet 111 (1999) 7-17
10. Ahuja H., Bar-Eli M., Advani S.H., Benchimol S., and Cline M.J. Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia. Proc Natl Acad Sci USA 86 (1989) 6783-6787
11. Collins S.J., Howard M., Andrews D.F., Agura E., and Radich J. Rare occurrence of N-ras point mutations in Philadelphia chromosome positive chronic myeloid leukemia. Blood 73 (1989) 1028-1032
12. Sokal J.E., Cox E.B., Baccarani M., Tura S., Gomez G.A., Robertson J.E., Tso C.Y., Braun T.J., Clarkson B.C., Cervantes F., and Rozman C. The Italian coperative CML study group. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 63 (1984) 789-799
13. Lee D.S., Lee Y.S., Yun Y.S., Kim Y.R., Jeong S.S., Lee Y.K., She C.J., Yoon S.S., Shin H.R., Kim Y., and Cho H.I. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its association with disease progression. Genes Chromosomes Cancer 37 (2003) 291-299
14. Kantarjian H.M., Keating M.J., Talpaz M., Walters R.S., Smith T.L., Cork A., McCredie K.B., and Freireich E.J. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med 83 (1987) 445-454
15. Czepulkowski B.H., Bhatt B., and Rooney D.E. Basic techniques for the preparation and analysis of chromosomes from bone marrow and leukaemic blood. In: Rooney D.E., and Czepulkowski B.H. (Eds). Human Cytogenetics. A Practical Approach vol. II (1992), Oxford University Press, New York 1-25
16. In: Mitelman F. (Ed). ISCN: An International System for Human Cytogenetic Nomenclature (1995), S. Karger, Basel
17. Chomczynski P., and Sacchi N. Single-step method of RNA isolation by acid thiocyanate-phenolchloroform extraction. Anal Biochem 162 (1987) 156-159
18. Maurer J., Kinzel H., Nentwig T., and Thiel E. Molecular diagnosis of the Philadelphia chromosome in chronic myelogenous and acute lymphoblastic leukemia by PCR. Dis Markers 8 (1990) 211-218
19. Werner M., Ewig M., Nasarek A., Wilkens L., von Wasielewski R., Tchinda J., and Nolte M. Value of fluorescence in situ hybridization for detecting the bcr/abl gene fusion in interphase cells of routine bone marrow specimens. Diagn Mol Pathol 6 (1997) 282-287
20. Huntly B.J., Reid A.G., Bench A.J., Campbell L.J., Telford N., Shepherd P., Szer J., Prince H.M., Turner P., Grace C., Nacheva E.P., and Green A.R. Deletions of the derivative chromosome 9 occur at the time of the Philadelphia translocation and provide a powerful and independent prognostic indicator in chronic myeloid leukemia. Blood 98 (2001) 1732-1738
21. Gratwohl A., Hermans J., Niederwieser D., Frassoni F., Arcese W., Gahrton G., Bandini G., Carreras E., Vernant J.P., Bosi A., de Witte T., Fibbe W.E., Zwaan F., Michallet M., Ruutu T., Devergie A., Iriondo A., Apperley J., Reiffers J., Speck B., and Goldman J. Bone marrow transplantation for chronic myeloid leukemia: long-term results. Chronic Leukemia Working Party of the European Group for Bone Marrow Transplantation. Bone Marrow Transplant 12 (1993) 509-516
22. Italian Cooperative Study Group on Chronic Myeloid Leukemia. Interferon alfa-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia. N Engl J Med 330 (1994) 820-825
23. Diekmann D., Brill S., Garrett M.D., Totty N., Hsuan J., Monfries C., Hall C., Lim L., and Hall A. Bcr encodes a GTPase-activating protein for p21rac. Nature 351 (1991) 400-402
24. Wu Y., Ma G., Lu D., Lin F., Xu H.J., Liu J., and Arlinghaus R.B. Bcr: a negative regulator of the Bcr-Abl oncoprotein. Oncogene 18 (1999) 4416-4424